Method for preparing vilanterol triphenylacetate

The one-pot process for preparing vilanterol triphenylacetate addresses inefficiencies in existing methods by directly converting starting materials into the final product, improving yield and purity while reducing waste and purification steps.

JP2024545468APending Publication Date: 2024-12-06HOVIONE SCIENTIA LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024538103
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-22
Filing Date
2022-12-19
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing methods for preparing vilanterol and its pharmaceutically acceptable salts, such as vilanterol triphenylacetate, are inefficient, require extensive purification steps, and produce undesirable impurities, making them impractical for industrial processes.

Method used

A novel method involving a one-pot or abbreviated process that skips intermediate isolation and purification steps, using specific chemical reactions to directly convert starting materials into vilanterol or its salts, reducing the need for chromatographic purification and isolation of intermediates.

Benefits of technology

This approach enhances process efficiency, reduces time and resource consumption, and minimizes waste generation while achieving high yields and purity of vilanterol triphenylacetate, suitable for industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545468000001
    Figure 2024545468000001
  • Figure 2024545468000002
    Figure 2024545468000002
  • Figure 2024545468000003
    Figure 2024545468000003
Patent Text Reader

Abstract

In one aspect, the method for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Compound VI) or a pharma- ceutically acceptable salt thereof comprises the following steps, in which steps A through B(i) are carried out as a one-pot or shortened process: A) reacting the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxo-4H-1,3-benzodioxin-6-yl) with the compound (5R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; B) coupling sazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in an organic solvent; and B) (i) adding a base to the reaction mixture formed in step A to remove the oxazolidinone protecting group to form compound V; and (ii) converting compound V to vilanterol (compound VI) or a pharma- ceutically acceptable salt thereof. In another aspect, a method for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Compound VI) or a pharma- ceutically acceptable salt thereof comprises coupling the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (Compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (Compound III) and converting the product formed to vilanterol or a pharma- ceutically acceptable salt thereof, during which no intermediate compound or only one is isolated.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] [Field of the Invention] The present invention relates generally to novel methods for preparing vilanterol and its pharma- ceutically acceptable salts. More particularly, the present invention relates to new methods for preparing intermediates for preparing vilanterol in batch or continuous flow mode. These new synthetic methods offer advantages over known routes, including reduced process time, resources, and reduced waste.

[0002] [Background of the invention] Vilanterol triphenylacetate (I) has the chemical name (R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol 2,2,2-triphenylacetate [CAS: 503070-58-4] and the following molecular structure: [ka] Vilanterol triphenylacetate (I) is a long-acting beta-adrenergic receptor agonist (LABA) with the following properties: Vilanterol triphenylacetate (I) was first claimed by GlaxoSmithKline in WO 2003 / 024439. It has been approved for use in combination products, such as with fluticasone furoate under the trade names Breo Ellipta®; with umeclidinium bromide under the trade name Anoro Ellipta® (FDA approved in 2013); and with both under the trade name Trelegy Ellipta® (FDA approved in 2017). The combination product is indicated for the treatment of chronic obstructive pulmonary disease (COPD).

[0003] Methods for preparing vilanterol and its pharma- ceutically acceptable salts are disclosed in WO 2003 / 024439, in the corresponding patent application US 7361787, and in J. Med. Chem. 2010, 53, 4522-4530. The reported synthetic sequence includes the preparation of compound II and compound III (Scheme 1). These key intermediates are coupled in the presence of potassium tert-butoxide to form compound IV. Oxazolidinone cleavage is carried out in the presence of 4 equivalents of potassium trimethylsilanolate (KOTMS) in THF to give compound V. The acetal protecting group is removed under ethanolic acidic conditions to form vilanterol base (compound VI). The latter is converted to the corresponding triphenatate salt in ethanol at 80°C.

[0004] [ka]

[0005] The method described in WO 2003 / 024439 presents some difficulties. The method requires 4 equivalents of KOTMS at reflux temperature to cleave the oxazolidinone ring. In addition, the method uses an alcohol solvent for acetal cleavage, which is prone to form the corresponding ether impurity. The method requires cumbersome purification, such as large-scale liquid-liquid extraction or chromatographic purification, to purge the impurities, which is not practical for industrial processes.

[0006] Other companies have claimed to improve upon the original synthetic route. Laurus Labs, in WO 2014 / 041565 (US 2015 / 0239862), reports the preparation of vilanterol triphenylacetate in alternative alcoholic solvents such as methanol and isopropanol. However, the use of these solvents is reported to have no exceptional effect on yield or purity. Alternatively, the patent claims that the use of a non-alcoholic solvent, preferably acetone, results in a reduced impurity profile (>99.5% purity by HPLC, no single impurity above 0.1%). This step involves the addition of a triphenylacetic acid slurry to a solution of compound VI, both in acetone, and heating to 50-55°C (WO 2014 / 041565, Example 13). Vilanterol triphenylacetate is obtained with a purity of 99.79%. In this case, the main improvement is made for the last step, but the difficulty of the whole process remains.

[0007] China Patent No. 111807973 (Shanghai Anovent Pharmaceutical Co Ltd) discloses a method for preparing vilanterol and relies on the use of succinic acid. WO 2017001907 (Teva) also relates to the preparation of vilanterol, but employs a biocatalytic conversion process involving polypeptides. WO 2021033198 (Melody Healthcare PVT Ltd.) employs the use of tetrabutylammonium hydrogen sulfate (TBAHS) in catalytic amounts in a complex process.

[0008] Israeli Patent Application No. 233520 describes a similar synthetic strategy to prepare vilanterol from compound II and compound III. In this case, it is disclosed that the use of DMF for the coupling step leads to undesired by-products, and the use of THF or DMSO as an alternative solvent is proposed to prepare compound IV. The coupling reaction carried out in DMSO requires high temperature (70° C.) to obtain compound IV with a purity of up to 95 area % by HPLC, while the purity drops to 75.5 area % in the reaction carried out in THF. Moreover, all intermediates are still isolated by extraction procedures.

[0009] The inventors have reviewed these previous reports and now recognized that a need remains to develop more efficient methods for preparing vilanterol and its pharma- ceutically acceptable salts. As a result of this, the inventors have now devised the present invention, which overcomes or substantially minimizes many of the difficulties found in the previous methods.

[0010] The inventors have found that compound V and compound VI, as well as their own salts (e.g., compound I), can be efficiently produced by a shortened approach that shows improved yields and similar impurity profiles while avoiding the existing extensive extraction and isolation steps that have been examined in the prior art. This approach allows the preparation of vilanterol triphenylacetate in a one- or two-step process, which is a relevant improvement when compared to previous strategies that include four synthetic steps. In this manner, vilanterol salts are obtained by a process that shows excellent efficiency, time, resource and waste conservation. In particular, there is only the isolation of at most one intermediate (compound V).

[0011] [Summary of the Invention] The present invention relates to a novel method for preparing vilanterol and its pharma- ceutically acceptable salts, particularly vilanterol triphenylacetate, in batch or continuous flow mode.The present invention relates in particular to a shortened method for preparing vilanterol intermediates, in which starting materials are subjected to successive chemical reactions without workup after each reaction and without isolating intermediates.This approach avoids several isolation and purification steps, thus increasing process efficiency and chemical yield.

[0012] Scheme 2 depicts a synthetic sequence that includes abbreviated steps to afford compounds of formula I.

[0013] [ka]

[0014] Scheme 3 depicts a method for obtaining compounds of formula I, where the intermediate compounds are not isolated.

[0015] [ka]

[0016] According to one aspect of the present invention, there is provided a process for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Compound VI) or a pharma- ceutically acceptable salt thereof, comprising the steps A to B(i) of the following steps carried out as a one-pot or shortened process: A) coupling compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in an organic solvent; and B) (i) adding a base to the reaction mixture formed in step A to remove the oxazolidinone protecting group to form compound V; (ii) converting compound V into vilanterol (compound VI) or a pharma- ceutically acceptable salt thereof.

[0017] As described herein, there is no isolation of an intermediate compound (e.g., compound IV) from the reaction mixture until compound V is obtained in step B(i). Compound V may then be optionally isolated and subsequently converted to vilanterol or a pharma- ceutically acceptable salt thereof. Alternatively, as described further below, in one embodiment, compound V is not isolated. The method can be continued as a shortened or one-pot process to directly obtain vilanterol or a pharma- ceutically acceptable salt thereof, e.g., vilanterol triphenylacetate.

[0018] The present invention therefore encompasses a method for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Compound VI) or a pharma- ceutically acceptable salt thereof, comprising coupling the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (Compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (Compound III) and converting the product formed to vilanterol, wherein only one intermediate compound is isolated. For example, this intermediate compound may be Compound V. Said conversion may, for example, be as described in the process steps above.

[0019] According to another aspect of the present invention, there is provided a process for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; compound VI) or a pharma- ceutically acceptable salt thereof, comprising the following steps, in which steps A to C are carried out as a one-pot or shortened process: A) coupling compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in an organic solvent; B) adding a base to the reaction mixture formed in step A to remove the oxazolidinone protecting group; and C) adding an acidic solution to the reaction mixture formed in step B to cleave the acetonide protecting group to form vilanterol (compound VI); D) Optionally, a process is provided which comprises converting compound VI into a pharma- ceutically acceptable salt thereof.

[0020] As described herein, in this embodiment, there is no isolation of an intermediate compound (e.g., compound IV or V) from the reaction mixture until compound VI is obtained in step C. Compound VI (vilanterol) may then be optionally isolated and subsequently converted to its pharma- ceutically acceptable salt, e.g., vilanterol triphenylacetate, as appropriate. Alternatively, as described further below, in one embodiment, compound VI is not isolated. The method can be continued as a shortened or one-pot process to directly obtain a pharma- ceutically acceptable salt of vilanterol, e.g., vilanterol triphenylacetate.

[0021] The present invention therefore encompasses a method for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; compound VI) or a pharma- ceutically acceptable salt thereof, comprising the steps of coupling the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) and converting the product formed to vilanterol, wherein no intermediate compound is isolated. Said conversion may, for example, be as described in the process steps above.

[0022] In a further aspect, a method for preparing a pharma- ceutically acceptable salt of vilanterol, comprising the steps of: A) coupling compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in an organic solvent; B) adding a base to the reaction mixture formed in step A to remove the oxazolidinone protecting group; and C) adding an acidic solution to the reaction mixture formed in step B to cleave the acetonide protecting group to form vilanterol (compound VI); D) converting compound VI into a pharma- ceutically acceptable salt thereof.

[0023] As described herein, in this embodiment, there is no isolation of an intermediate compound (e.g., compound IV, V, or VI) from the reaction mixture until a pharma- ceutically acceptable salt of vilanterol, e.g., vilanterol triphenylacetate, is obtained in step D. The pharma- ceutically acceptable salt of vilanterol, e.g., vilanterol triphenylacetate, may then be isolated and further purified. In this embodiment, the method may thus be operated as a shortened or one-pot process to directly obtain a pharma- ceutically acceptable salt of vilanterol, e.g., vilanterol triphenylacetate.

[0024] The present invention therefore encompasses a method for preparing a pharma- ceutically acceptable salt of vilanterol, comprising coupling the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) and converting the product formed into a pharma- ceutically acceptable salt of vilanterol, wherein no intermediate compound is isolated. Said conversion may, for example, be as described in the process steps above.

[0025] In a preferred embodiment of the invention, the pharma- ceutically acceptable salt of vilanterol is vilanterol triphenylacetate.

[0026] In one embodiment, the method does not require any purification, in particular, for example, chromatographic purification of the intermediate compound.Thus, the present invention includes the feature of not carrying out purification, in particular not carrying out chromatographic purification, on the intermediate compound produced during the course of the process.Such intermediates may include compound IV, or compound V, or compound VI; or both compounds IV and V, or all of compounds IV, V, and VI, depending on the process used.

[0027] The same is true for isolating intermediate compounds. Thus, the present invention includes the feature that isolation is not performed on one or more intermediate compounds(s) produced during the course of the process. Such intermediates may include compound IV, or compound V, or compound VI; or both compounds IV and V, or all of compounds IV, V, and VI, depending on the process used.

[0028] In another aspect, the present invention provides a method for preparing (R)-3-{6-[2-(2,6-dichlorobenzyloxy)-ethoxy]-hexyl}-5-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-oxazolidin-2-one 2,2,2-triphenylacetate (Compound I), also known as vilanterol triphenylacetate, comprising the steps of: 1. The following: A. coupling of compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; B. adding a base to the reaction mixture to remove the oxazolidinone protecting group; and C. A shortened process including the step of adding an acidic solution to the reaction mixture to remove the acetonide protecting group to form compound VI; and 2. Reacting compound VI with triphenylacetic acid to form compound I in a suitable organic solvent.

[0029] In another aspect, the present invention provides an alternative method for preparing (R)-3-{6-[2-(2,6-dichlorobenzyloxy)-ethoxy]-hexyl}-5-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-oxazolidin-2-one 2,2,2-triphenylacetate (Compound I), also known as vilanterol triphenylacetate, comprising the following steps: 1. The following: A. coupling of the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; and B. A shortened process including the step of adding a base to the reaction mixture to remove the oxazolidinone protecting group to form compound V; and 2. Removal of the acetonide protecting group in the presence of an acidic solution in a suitable organic solvent to produce compound VI; and 3. Reacting compound VI with triphenylacetic acid to form compound I in a suitable organic solvent.

[0030] In another aspect of the present invention, there is provided a process for preparing (R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol (Compound VI), also known as vilanterol, comprising the steps of: below: A. coupling of compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; B. adding a base to the reaction mixture to remove the oxazolidinone protecting group; and C. A method is provided that includes a shortened step of adding an acidic solution to the reaction mixture to cleave the acetonide protecting group to form compound VI.

[0031] In a further aspect of the invention, there is provided a process for preparing (R)-2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethan-1-ol (Compound V), comprising the steps of: below: A. coupling of the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; and B. A method is provided that includes a shortened step that includes adding a base to the reaction mixture to remove the oxazolidinone protecting group to form compound V.

[0032] One-pot or shortened process essentially means that a process is carried out without any isolation of intermediate compounds from the reaction mixture. Thus, the usual steps of isolation of intermediate compounds, as well as work-up or purification, can be avoided. The final compound (with respect to the process step in question) can be obtained directly by a series of reactions carried out sequentially or consecutively, for example in a single vessel or pot, which may include, for example, continuous flow reactor(s). This approach is also known as shortening, as will be understood by those skilled in the art. Thus, in one embodiment, compound V can be obtained directly from compounds II and III without isolation of any intermediates, for example compound IV. Similarly, in another embodiment of the present invention, vilanterol itself (compound VI) or its salts, for example vilanterol triphenylacetate (compound I), can be obtained directly from compounds II and III, without isolation of any intermediates. The compounds are obtained in excellent yields and in a more efficient manner.

[0033] In the present invention, vilanterol or its pharma- ceutically acceptable salt, such as vilanterol triphenylacetate, is obtained using a method that shows excellent efficiency, thus saving time, resources and waste.In particular, there is only one intermediate (compound V) isolation at most, although in some embodiments, as described further, this isolation may be unnecessary or avoided.This method does not require chromatographic purification, reducing cycle time and process waste.

[0034] The present invention thus describes a novel method for producing vilanterol salts, particularly vilanterol triphenylacetate salts. One of the methods involves an efficient two-step approach using compound II and compound III as raw materials to form compound VI by abbreviated (i.e., one-pot process) in batch or continuous flow mode. In this abbreviated (i.e., one-pot process) batch or continuous flow process, intermediate compound IV is not isolated but is directly converted to intermediate compound V. Subsequently, intermediate compound V is not isolated but is directly converted to intermediate compound VI. The method avoids several isolation and purification steps in both batch and continuous flow modes.

[0035] In an alternative process, vilanterol triphenylacetate is obtained in a three-step approach. In this case, compound VI is prepared from compound V, which is prepared from compound II and compound III by abbreviated (i.e., one-pot process) in batch or continuous flow mode. More specifically, intermediate compound IV is not isolated but is directly converted to compound V. As a final step, vilanterol (compound VI) can then be converted to its pharma- ceutically acceptable salt, preferably vilanterol triphenylacetate (compound I). In an alternative process, the inventors have found that the entire process can also be effectively carried out in one step starting from compounds II and III as a one-pot or shortened process. Thus, the inventors have found that a pharma- ceutically acceptable salt of vilanterol, preferably vilanterol triphenylacetate (compound I), can be obtained directly by the methods disclosed herein without any isolation of intermediate compounds.

[0036] Compounds V, VI and I are obtained in all of the shortened (i.e. one-pot) processes described herein in batch or continuous flow mode in excellent yields and by the shortened (i.e. one-pot) processes without the need for chromatographic separation.

[0037] In one aspect of the invention, the methods described herein do not require the use of succinic acid.

[0038] In a further aspect, the methods described herein do not employ biocatalytic conversion processes or the use of polypeptides.

[0039] [Detailed Description of the Invention] The present invention relates to a novel method for preparing vilanterol and its pharmaceutically acceptable salts, such as vilanterol triphenylacetate in particular.The method of the present invention described herein can be carried out, for example, in batch or continuous flow mode.More specifically, the present invention relates to a new method for preparing compound V and compound VI, which are involved in the preparation of vilanterol triphenylacetate.

[0040] In one process, vilanterol (Compound VI) or a pharma- ceutically acceptable salt thereof, such as vilanterol triphenylacetate (Compound I), can be prepared by the following steps: 1. The following: A. coupling of compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; B. adding a base to the reaction mixture to remove the oxazolidinone protecting group; and C. A shortened step or one-pot process comprising adding an acidic solution to the reaction mixture for acetonide protecting group cleavage to form compound VI; and 2. Reacting compound VI with triphenylacetic acid to form vilanterol triphenylacetate (compound I).

[0041] According to the present invention, the method comprises a shortened step, or one-pot process, for producing compound VI from compound II and compound III, which can be carried out in batch or continuous flow mode.

[0042] The reaction (e.g., step A) may be carried out in any suitable organic solvent in any embodiment of the method. Polar aprotic solvents are particularly suitable. The polar aprotic solvent may be selected from the group consisting of, for example, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide (DMAc), n-methyl-pyrrolidin-2-one (NMP), tetrahydrofuran (THF), sulfolane or mixtures thereof, preferably DMSO.

[0043] In particular, in one preferred embodiment, the same solvent may be used for all process steps until compound V or compound VI (vilanterol) or a salt thereof is produced, with DMSO being preferred for this.

[0044] The volume of the solvent may be, for example, at least 10 volumes, or 10 to 30 volumes, preferably about 25 volumes, relative to the volume of compound II.

[0045] According to the present invention, step A comprises coupling compound II with compound III in the presence of a base. Compound III can be in excess relative to compound II, preferably up to 1.5 molar equivalents, and more preferably compound III is present in about 1.05 to 1.1 molar equivalents relative to compound II. In some embodiments, about 1.25 molar equivalents of base can be used relative to compound II.

[0046] The base may be any base suitable for this reaction. For example, the base may be selected from the group consisting of alkali metal hydroxide, alkali metal hydride, such as sodium hydride; alkali metal alkoxide, such as sodium tert-butoxide, potassium tert-butoxide, preferably potassium tert-butoxide. The base may be used in at least a stoichiometric amount or more relative to compound II, preferably about 1 to about 1.15 molar equivalents of base, or about 1.1 molar equivalents of base may be used. In continuous flow mode, the base is preferably used in at least a stoichiometric amount or more relative to compound II, preferably about 1.15 to 3 molar equivalents of base relative to compound II, or about 1.25 molar equivalents of base relative to compound II.

[0047] The reaction is preferably carried out at a temperature between 20° C. and 40° C., in particular between 20° C. and 30° C. The reaction may be carried out for 1 to 6 hours, preferably between 1 to 2 hours. In batch mode, step A is preferably carried out at a temperature between 20 and 30° C., preferably between 20 and 25° C.

[0048] According to the present invention, once step A is complete as verified by HPLC, step B involves adding a suitable base directly to the reaction mixture to carry out the second transformation, which is oxazolidinone ring cleavage, without carrying out workup of the first reaction. Step B may also include adding water to the reaction mixture. When used, water may be used in an amount of, for example, up to 3 molar equivalents, preferably about 1.5 to 3 molar equivalents relative to compound II. The base may be any base suitable for carrying out this step, but is preferably selected from the group consisting of sodium or potassium trialkylsilanolate, such as potassium trimethylsilanolate; alkali metal alkoxide, such as sodium tert-butoxide or potassium tert-butoxide, preferably potassium tert-butoxide. The base is used in an amount of up to 3 molar equivalents, preferably about 1.5 to 2 molar equivalents relative to compound II. In batch mode, the base used in step B is typically used in an amount of 1 to 3 molar equivalents relative to compound II, preferably about 1.5 molar equivalents relative to compound II.

[0049] In one aspect of the invention, the method does not employ the use of potassium trimethylsilanolate (KOTMS).

[0050] In another aspect of the invention, the process may eliminate the use of THF as a solvent, for example in step B of the process.

[0051] In another aspect of the invention, the process may eliminate the use of acetone as a solvent, for example in step C of the process. The inventors have found that this reduces impurity levels.

[0052] The reaction may be carried out, for example, for 1 to 6 hours, preferably 1 to 2 hours. The reaction may be carried out, for example, at a temperature of 30 to 65° C., preferably 35 to 50° C. For example, in batch mode, the reaction is typically carried out at a temperature of 30 to 65° C., preferably 35 to 50° C.

[0053] In some preferred embodiments, the reacting is carried out for up to 6 hours at about 50° C. until reaction completion. Preferably, the reacting step is carried out for 2 hours at about 50° C. until reaction completion.

[0054] According to the present invention, once step B is complete as verified by HPLC, step C involves adding an acid directly to the reaction mixture to carry out the third reaction, which is the removal of the acetal protecting group. The acidic solution may be selected from the group consisting of 0.1-1N HCl aqueous solution, 1-10% HCl alcohol solution, HCl dissolved in a suitable organic solvent, such as DMF-HCl, ether-HCl, acetic acid-HCl, and is preferably an aqueous HCl solution, such as 1N HCl aqueous solution. The acidic solution may be added to the reaction mixture at a temperature of 0-25°C, preferably 0-5°C. The addition of the acid to the reaction mixture may be carried out over a period of up to 4 hours, preferably about 1-2 hours. The reaction may be carried out at a temperature of 20-30°C, preferably 20-25°C. The reaction may be carried out over a period of 2-10 hours, preferably 4-6 hours. Once the shortened step is complete, the reaction mixture may be cooled and neutralized with aqueous sodium bicarbonate solution, followed by extraction with an organic solvent. The cooling is carried out at a temperature below 20°C, preferably 10-15°C. The extraction is carried out with an organic solvent which may be selected from the group consisting of, for example, esters and halogenated hydrocarbons, such as ethyl acetate or dichloromethane, preferably ethyl acetate.

[0055] According to the present invention, compound VI obtained by the above procedure has an overall purity of more than 90%, preferably more than 95%, as determined by HPLC.

[0056] According to the present invention, compound VI obtained by the above procedure has a chiral purity of more than 99% by HPLC, preferably more than 99.85% as measured by HPLC.

[0057] According to the present invention, in a continuous flow mode, steps A, B and C may include reacting a solution of compound II and a base in a flow reactor to form a deprotonated compound II, reacting a solution of deprotonated compound II and compound III in a flow reactor to form compound IV, reacting compound IV and a base in a flow reactor to form compound V, and reacting compound V and an acid in a flow reactor or in a batch reactor to form compound VI. The reaction mixture containing compound IV may be fed directly to the flow reactor in step B, or may be collected in a buffer tank and fed to the flow reactor for step B. The reaction mixture containing compound V may be fed directly to the flow reactor for step C, or may be collected in a buffer tank and fed to the flow reactor for step C.

[0058] According to the present invention, step A in continuous flow mode comprises reacting a solution of compound II and a base in a flow reactor to form a deprotonated compound II, and reacting a solution of deprotonated compound II and compound III in a flow reactor to form compound IV. The solutions of compound II and compound III can be suitably prepared in a polar aprotic solvent, which can be selected from the group consisting of dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide (DMAc), n-methyl-pyrrolidin-2-one (NMP), tetrahydrofuran (THF), sulfolane or mixtures thereof, preferably DMSO. The volume of the solvent can be at least 10 volumes, preferably about 25 volumes, relative to the volume of compound II. Compound III can be in excess, preferably present in up to 1.5 molar equivalents, preferably about 1.05 molar equivalents, relative to compound II. The base may be any suitable base, but is preferably selected from the group consisting of alkali metal hydroxides, alkali metal hydrides, such as sodium hydride; alkali metal alkoxides, such as sodium tert-butoxide, potassium tert-butoxide, and is preferably potassium tert-butoxide. The base is preferably used in at least a stoichiometric amount, preferably 1.25 equivalents. In the reaction of compound II with a base, the temperature in the continuous flow reactor is preferably in the range of 20°C to 100°C, preferably about 20°C. Preferably, the flow rate is adjusted to arrange for a residence time of 0.5 min to 30 min, preferably about 2 to 15 min, for example about 6 min. In the reaction of deprotonated compound II with compound III, the temperature in the continuous flow reactor is preferably in the range of 20°C to 100°C, preferably about 60°C. Preferably, the flow rate is adjusted to arrange for a residence time of 0.5 min to 30 min, preferably about 2 to 15 min, for example about 6 min. According to the present invention, in step B, the continuous flow mode suitably comprises reacting a reaction mixture containing compound IV and a base in a continuous flow reactor.The base may be any base suitable for this step, but is preferably selected from the group consisting of sodium or potassium trialkylsilanolate, such as potassium trimethylsilanolate; alkali metal alkoxide, such as sodium or potassium tert-butoxide, preferably potassium tert-butoxide. The base is preferably used in an amount of up to 15 molar equivalents relative to compound II, preferably about 4-5 molar equivalents relative to compound II. The temperature in the continuous flow reactor is, for example, in the range of 20° C. to 150° C., preferably around 80° C. The flow rate may be suitably adjusted, typically resulting in a residence time in the range of 0.5 min to 30 min, preferably around 2-10 min, for example around 4 min.

[0059] According to the present invention, in step C, the continuous flow mode comprises reacting a reaction mixture containing compound V and an acid in a continuous flow reactor, or directing a reaction mixture containing compound V to a batch reactor containing an acid to form compound VI. The acid can be any acid suitable for carrying out this step, such as any acidic solution suitable for achieving acetal hydrolysis in step C, but is preferably selected from the group consisting of 0.1-1N HCl aqueous solution, 1-10% HCl alcohol solution, HCl dissolved in a suitable organic solvent, such as DMF-HCl, ether-HCl, acetic acid-HCl, and is preferably an HCl aqueous solution, such as 1N HCl aqueous solution. The acid can be used in excess, preferably about 1.5 molar equivalents, relative to compound II.

[0060] The temperature in a continuous flow or batch reactor is typically in the range of 20° C. to 100° C., preferably around 20° C. In batch mode, step C is preferably carried out at a temperature of about 20° C. to 30° C., in particular about 20° C. to 25° C. In continuous flow mode, step C is preferably carried out at a temperature of about 20° C. to 100° C., preferably around 20° C.

[0061] In continuous flow mode, in step C, the flow rate is typically adjusted to give a residence time in the range of 0.5 min to 30 min, preferably around 10 min. In batch mode, the reaction may be carried out for 2 to 10 hours, preferably 4 to 6 hours. The reaction mixture collected in the shortened batch or continuous flow process to form compound VI is cooled, neutralized with aqueous sodium bicarbonate, and subsequently extracted with an organic solvent. Cooling is carried out at a temperature below 20° C., preferably 10 to 15° C. Extraction is carried out with an organic solvent which may be suitable, selected from the group consisting of esters and halogenated hydrocarbons, such as ethyl acetate or dichloromethane, preferably ethyl acetate.

[0062] According to the present invention, compound VI obtained as in the above process from step A to C can be converted into a pharma- ceutically acceptable salt as the last step of the process, which comprises reacting compound VI obtained by shortening with a suitable acid, preferably triphenylacetic acid, in the presence of a suitable solvent. The use of this acid gives vilanterol triphenylacetate as the final product, which is preferred.

[0063] According to the present invention, compound V obtained as in the above process from step A to B can be converted to compound VI which is converted to a pharma-ceutically acceptable salt as the last step of the process, which comprises reacting compound VI obtained by shortening with a suitable acid, preferably triphenylacetic acid, in the presence of a suitable solvent. The use of this acid gives vilanterol triphenylacetate as the final product, which is preferred.

[0064] According to the present invention, the final step may, for example, comprise dissolving compound VI in a suitable solvent and adding triphenylacetic acid to form vilanterol triphenylacetate. The reaction is suitably carried out in a polar aprotic solvent, which may, for example, be selected from the group consisting of methylene chloride (DCM), ethyl acetate, THF, DMF, acetone, acetonitrile or mixtures thereof, preferably acetone.

[0065] Also according to the invention, in a further aspect, the step of converting vilanterol to a pharma- ceutically acceptable salt, such as vilanterol triphenylacetate, as described above, may also form part of a one-pot process. That is, a shortened reaction (i.e., a one-pot process) may include all steps from step A until the salt is formed. This may be carried out in batch or continuous flow mode.

[0066] Therefore, if necessary, compound I can be obtained by shortening, for example, a one-step approach using compounds II and III as raw materials in batch mode. In this shortened batch process, intermediate VI is not isolated, but is directly converted to compound I. The process avoids several distillations, isolations and purifications, since compound I can be directly isolated from the reaction mixture by precipitation. In this way, compound I is prepared in good yield and good purity. Optionally, recrystallization of compound I can be performed.

[0067] According to the present invention, compound I (vilanterol triphenylacetate) can be prepared, for example, by the following steps: 1. The following: A. coupling of compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; B. A shortened batch or continuous flow process comprising the step of adding a base to the reaction mixture to remove the oxazolidinone protecting group to form compound V; and 2. Removal of the acetonide protecting group in the presence of an acidic solution in a suitable organic solvent to produce compound VI; and 3. Reacting compound VI with triphenylacetic acid to form compound I.

[0068] The present invention relates to a process for preparing compound V from compound II and compound III, comprising: A. coupling of the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; and B. adding a base to the reaction mixture to remove the oxazolidinone protecting group to form compound V.

[0069] Compound V may then be isolated and purified, if necessary, and subsequently converted to compound VI, which may then suitably be converted to a pharma- ceutically acceptable salt, such as vilanterol triphenylacetate.

[0070] The present invention therefore relates to a process for preparing compound VI from compound II and compound III, comprising: A. coupling of compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in a suitable organic solvent; B. adding a base to the reaction mixture to remove the oxazolidinone protecting group; and C. adding an acidic solution to the reaction mixture for cleavage of the acetonide protecting group to form compound VI.

[0071] The present invention therefore also includes a method for preparing vilanterol triphenylacetate (compound I) according to the process steps described herein, comprising as a final step reacting compound VI with triphenylacetic acid to form vilanterol triphenylacetate (compound I).

[0072] The present invention relates to a method for preparing vilanterol triphenylacetate (Compound I) according to the process steps described herein, comprising, as a final step: i) removing the acetonide protecting group from compound V in an acidic solution to form compound VI; and ii) reacting compound VI with triphenylacetic acid to form compound I.

[0073] The following examples illustrate the present invention but are not intended to be construed as limiting thereof. EXAMPLES

[0074] Example 1 A shortened procedure for the synthesis of (R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol (vilanterol) Potassium tert-butoxide (1.98 g, 1.1 equiv.) is added to a solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (4 g, 16 mmol) in DMSO (15 vol) under N2 atmosphere and the reaction is stirred at room temperature for 1 hour. A solution of 2-[2-(6-bromo-hexyloxy)-ethoxymethyl]-1,3-dichloro-benzene (6.47 g, 1.1 equiv.) in DMSO (10 vol) is added to the reaction mixture and stirred at room temperature until the reaction is complete according to HPLC. Potassium tert-butoxide (2.70 g, 1.5 equiv.) is then added to the reaction mixture and the reaction mixture is heated to 50° C. until complete conversion according to HPLC. The reaction mixture is cooled and 15% of 1M aqueous HCl (4.5 equiv) is added dropwise to the reaction mixture. The reaction mixture is cooled to 0-5°C and the remaining 1M aqueous HCl is added dropwise. The reaction is stirred at 5°C for 1 hour and then at room temperature until the reaction is complete according to HPLC. The reaction mixture is cooled to 10-15°C and neutralized with 1M aqueous NaHCO3. The aqueous phase is extracted three times with ethyl acetate (10 vol). The combined organic layers are then washed with water (10 vol). The solvent is distilled and dried under vacuum to give compound VI as a brown oil (7.5 g, 96% yield, purity by HPLC: 90.9%).

[0075] Example 2 A shortened procedure for the synthesis of (R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol (vilanterol) Potassium tert-butoxide (1.29 g, 1.15 equiv.) is added to a solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (2.5 g, 10 mmol) in DMSO (15 vol) under N2 atmosphere and the reaction is stirred at room temperature for 1 h. A solution of 2-[2-(6-bromo-hexyloxy)-ethoxymethyl]-1,3-dichloro-benzene (4.04 g, 1.05 equiv.) in DMSO (10 vol) is added to the reaction mixture and stirred at room temperature until the reaction is complete according to HPLC. Potassium tert-butoxide (2.3 g, 2 equiv.) is then added to the reaction mixture and the reaction mixture is heated to 40° C. until complete conversion according to HPLC. The reaction mixture is cooled to about 15° C. and neutralized with 0.5 M aqueous HCl. The aqueous phase is extracted three times with ethyl acetate (20 vol). The combined organic layers are then washed with water (60 vol). The solvent is distilled and dried under vacuum to give compound VI as a brown oil (5.1 g, 96% yield, 82.1% purity by HPLC).

[0076] Example 3 General Procedure for the Synthesis of Vilanterol A solution of compound V (8.4 g, 16 mmol) in acetone (67 mL) was cooled to 5° C. Then, 0.5 M aqueous HCl (80 mL) was added dropwise and the mixture was stirred at this temperature for 1 h. The mixture was then stirred at room temperature until the reaction was complete according to HPLC. The reaction mixture was cooled to about 15° C. and neutralized with 1 M sodium bicarbonate solution (40 mL). The aqueous phase was extracted three times with ethyl acetate (33 mL). The combined organic layers were then washed with water (67 mL). The solvent was distilled and dried under vacuum to give compound VI as a brown oil (4.6 g, 59% yield, 82.1% purity by HPLC).

[0077] Example 4 General procedure for the synthesis of vilanterol triphenylacetate A slurry of triphenylacetic acid (4.2 g, 1 equiv.) in acetone (14 mL) was added to a solution of 4-((R)-2-{6-[2-(2,6-dichlorobenzyloxy)-ethoxy]-hexylamino}-1-hydroxyethyl-)-2-hydroxy-methyl-phenol (7 g, 14.4 mmol) in acetone (126 mL) and the mixture was heated to 50° C. until complete dissolution. The mixture was distilled to 12 vol at room temperature to induce precipitation. The reaction mixture was stirred at room temperature for up to 20 hours. The resulting product was filtered, washed with acetone (14 mL) and isopropyl ether (14 mL) and dried in vacuum at room temperature to give vilanterol triphenylacetate as a white crystalline solid (5.6 g, 75 w% yield, 96.6% purity by HPLC).

[0078] Example 5 Continuous flow procedure for the synthesis of compound IV A solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) (1 g, 4.01 mmol) in DMSO (10 mL) was injected (0.6 mL) at 20° C. with a flow rate of 0.012 mL / min and potassium tert-butoxide (0.56 g, 1.25 equiv.) in DMSO (10 mL). The resulting mixture and a solution of 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) (1.62 g, 1.05 equiv.) in DMSO (10 mL) were injected (0.4 mL) at 20° C. with a flow rate of 0.012 mL / min into the second PFA coil reactor. It is understood that the exact amounts and flow rates may be varied as desired. The product was not isolated, the reaction mixture was collected and analyzed by HPLC, which showed a conversion of 97%.

[0079] Example 6 Continuous flow procedure for the synthesis of compound IV A solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) (1 g, 4.01 mmol) in DMSO (10 mL) was injected (0.4 mL) at 20° C. with a flow rate of 0.033 mL / min and potassium tert-butoxide (0.68 g, 1.5 equiv.) in DMSO (10 mL) was injected (0.4 mL) at 20° C. The resulting mixture and a solution of 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) (1.62 g, 1.05 equiv.) in DMSO (10 mL) were injected (0.6 mL) at 60° C. with a flow rate of 0.033 mL / min into the PFA coil reactor. The product was not isolated, the reaction mixture was collected and analyzed by HPLC, which showed 93% conversion.

[0080] Example 7 Continuous flow procedure for the synthesis of compound IV A solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) (2 g, 8.02 mmol) in DMSO (10 mL) was injected (0.3 mL) at 20° C. with a flow rate of 0.033 mL / min and potassium tert-butoxide (1.12 g, 1.25 equiv.) in DMSO (10 mL) was injected (0.3 mL) at 20° C. The resulting mixture and a solution of 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) (3.08 g, 1.0 equiv.) in DMSO (10 mL) were injected (0.6 mL) at 100° C. with a flow rate of 0.033 mL / min. The product was not isolated, the reaction mixture was collected and analyzed by HPLC, which showed a conversion of 98.5%. The molar equivalents used in this example may result in fewer impurities.

[0081] Example 8 Continuous flow procedure for the synthesis of compound V A solution of compound IV (previously isolated from a batch trial) (2.22 g, 4.01 mmol) in DMSO (25 mL) at a flow rate of 0.05 mL / min and potassium tert-butoxide (0.4 g, 2.2 equiv.) in DMSO (10 mL) at a flow rate of 0.05 mL / min were injected (0.6 mL) into the PFA coil reactor at 80° C. The product was not isolated and the reaction mixture was collected and analyzed by HPLC, which showed a conversion of 90%.

[0082] Example 9 Continuous flow procedure for the synthesis of compound V A solution of compound IV (previously isolated from the batch trial (2.22 g, 4.01 mmol) in DMSO (25 mL) at 0.05 mL / min flow rate and potassium tert-butoxide (0.4 g, .4.4 equiv.) in DMSO (10 mL) at 0.1 mL / min flow rate were injected (0.6 mL) into the PFA coil reactor at 80° C. The product was not isolated and the reaction mixture was collected and analyzed by HPLC, which showed a conversion of 99.9%.

[0083] Example 10 Continuous flow procedure for the synthesis of compound VI A solution of compound V (previously isolated from a batch trial (1 g, 1.81 mmol)) in DMSO (8 mL) was injected (0.3 mL) at 0.15 mL / min flow rate and 1 M aqueous HCl (4.3 equiv.) at 0.15 mL / min flow rate into the PFA coil reactor at 20° C. The product was not isolated and the reaction mixture was collected and analyzed by HPLC, resulting in a conversion of 27%.

[0084] Example 11 Continuous flow procedure for the synthesis of compound VI A solution of compound V (1 g, 1.81 mmol) in DMSO (8 mL) was injected (0.3 mL) at 20° C. into the PFA coil reactor at a flow rate of 0.025 mL / min and 1M aqueous HCl (4.3 equiv.) at a flow rate of 0.025 mL / min. The product was not isolated, and the reaction mixture was collected and analyzed by HPLC, showing a conversion rate of 87%. The flow rates used in this example may reveal a higher conversion rate.

[0085] Example 12 Continuous flow procedure for the synthesis of truncated compound V A solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) (1 g, 4.01 mmol) in DMSO (10 mL) was injected (0.4 mL) at 20° C. with a flow rate of 0.033 mL / min and potassium tert-butoxide (0.68 g, 1.5 equiv.) in DMSO (10 mL). The resulting mixture and a solution of 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) (1.62 g, 1.05 equiv.) in DMSO (10 mL) were injected (0.6 mL) at 20° C. with a flow rate of 0.033 mL / min into the PFA coil reactor. The resulting mixture and potassium tert-butoxide (0.66 g, 13 equiv.) in DMSO (10 mL) were injected (0.6 mL) at a flow rate of 0.1 mL / min into a PFA coil reactor at 80° C. The product was not isolated, the reaction mixture was collected and analyzed by HPLC, which showed a conversion of 89.5%.

[0086] Example 13 A continuous flow procedure for the synthesis of the shortened compound VI A solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) (1 g, 4.01 mmol) in DMSO (10 mL) was injected (0.4 mL) at 20° C. with a flow rate of 0.033 mL / min and potassium tert-butoxide (0.68 g, 1.5 equiv.) in DMSO (10 mL). The resulting mixture and a solution of 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) (1.62 g, 1.05 equiv.) in DMSO (10 mL) were injected (0.6 mL) at 20° C. with a flow rate of 0.033 mL / min into the PFA coil reactor. The resulting mixture and potassium tert-butoxide (0.66 g, 13 equiv.) in DMSO (10 mL) was injected (0.6 mL) at 0.1 mL / min flow rate into a PFA coil reactor at 80° C. The resulting mixture and 1 M aqueous HCl was injected (2.4 mL) at 0.2 mL / min flow rate into a PFA coil reactor at 20° C. The product was not isolated and the reaction mixture was collected and analyzed by HPLC, which showed a conversion of 85%.

[0087] Example 14 A continuous flow procedure for the synthesis of the shortened compound VI A solution of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) (1 g, 4.01 mmol) in DMSO (10 mL) was injected (0.4 mL) at 20° C. with a flow rate of 0.033 mL / min and potassium tert-butoxide (0.68 g, 1.5 equiv.) in DMSO (10 mL). The resulting mixture and a solution of 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) (1.62 g, 1.05 equiv.) in DMSO (10 mL) were injected (0.6 mL) at 20° C. with a flow rate of 0.033 mL / min into the PFA coil reactor. The resulting mixture and potassium tert-butoxide (0.66 g, 13 equiv.) in DMSO (10 mL) were injected (0.6 mL) at 0.1 mL / min flow rate into a PFA coil reactor at 80° C. The resulting mixture was cooled to about 15° C. and neutralized with 1 M aqueous HCl. The product was not isolated, and the reaction mixture was collected and analyzed by HPLC, which showed a conversion of 88%.

[0088] Preparation of Pharmacologically Acceptable Vilanterol Salts. Example 15: Potassium tert-butoxide (9.4 g, 1.1 equiv.) is added to DMSO (15 vol.) under N2 atmosphere and the reaction is stirred at room temperature for 1 hour. (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (19.0 g, 76.1 mmol) is added and the reaction is stirred at room temperature for 1 hour. A solution of 2-[2-(6-bromo-hexyloxy)-ethoxymethyl]-1,3-dichloro-benzene (32.6 g, 1.09 equiv.) in DMSO (5 vol.) is added to the reaction mixture and stirred at room temperature until the reaction is complete according to HPLC. Water (2.1 mL, 1.5 eq.) and potassium tert-butoxide (18.0 g, 2.1 equiv.) are then added to the reaction mixture and the reaction mixture is heated to 35° C. until complete conversion according to HPLC. Cool the reaction mixture to 10°C and add 16% of 0.5M aqueous HCl (3.5 equiv.) dropwise to the reaction mixture. Stir the reaction mixture at 25°C and add the remaining 0.5M aqueous HCl dropwise. Stir the reaction at 25°C until the reaction is complete according to HPLC. Extract the aqueous phase with ethyl acetate (19.5 vol). Cool the reaction mixture to 10-15°C and neutralize with 1M aqueous Na2CO3. Extract the aqueous phase twice with ethyl acetate (10 vol). The combined organic layers are then washed with water (10 vol). Add the organic layer to a mixture of EtOAc (14 vol.) followed by triphenylacetic acid (22 g, 1.0 equiv) and stir at room temperature for 1 hour. Cool the reaction to 0°C and stir for 6 hours. Isolate the solid by filtration and wash twice with EtOAc (8 vol.). The solid is dried under vacuum to give Compound I as an off-white solid (37.8 g, 64% yield, purity by HPLC: 99.2%).

[0089] Example 16: Potassium tert-butoxide (14.9 g, 1.1 equiv.) is added to DMSO (15 vol.) under N2 atmosphere and the reaction is stirred at room temperature for 1 hour. (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (3.5 g, 14.1 mmol) is added and the reaction is stirred at room temperature for 1 hour. A solution of 2-[2-(6-bromo-hexyloxy)-ethoxymethyl]-1,3-dichloro-benzene (6.0 g, 1.09 equiv.) in DMSO (5 vol.) is added to the reaction mixture and stirred at room temperature until the reaction is complete according to HPLC. Water (0.76 mL, 3.0 eq.) and potassium tert-butoxide (2.5 g, 2.1 equiv.) are then added to the reaction mixture and the reaction mixture is heated to 35° C. until complete conversion according to HPLC. Water (3.5 mL) is added and the reaction mixture is cooled to 5° C. 0.5 M aqueous HCl (3.5 equiv.) is added dropwise to the reaction mixture. The reaction is stirred at 25° C. until the reaction is complete according to HPLC. The aqueous phase is extracted with ethyl acetate (19.5 vol). The reaction mixture is cooled to 10-15° C. and neutralized with 1 M aqueous Na2CO3. The aqueous phase is extracted twice with ethyl acetate (10 vol). The combined organic layers are then washed with water (10 vol). The organic layer is added to EtOAc (22 vol.) followed by triphenylacetic acid (4.1 g, 1.0 equiv) and stirred at room temperature for 1 h. The reaction is cooled to 0° C. and stirred for 6 h. The solid is isolated by filtration and washed twice with EtOAc (8 vol.). The solid is dried under vacuum to give compound I as an off-white solid (3.5 g, 32% yield, 99.4% purity by HPLC).

[0090] Example 17: Potassium tert-butoxide (4.21 g, 1.1 equiv.) is added to DMSO (15 vol.) under N2 atmosphere and the reaction is stirred at room temperature for 1 hour. (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (8.5 g, 34 mmol) is added and the reaction is stirred at room temperature for 1 hour. A solution of 2-[2-(6-bromo-hexyloxy)-ethoxymethyl]-1,3-dichloro-benzene (14.63 g, 1.09 equiv.) in DMSO (5 vol.) is added to the reaction mixture and stirred at room temperature until the reaction is complete according to HPLC. Water (0.95 mL, 1.5 eq.) and potassium tert-butoxide (8.0 g, 2.1 equiv.) are then added to the reaction mixture and the reaction mixture is heated to 35° C. until complete conversion according to HPLC. Water (8.5 mL) is added and the reaction mixture is cooled to 5° C. 0.5M aqueous HCl (3.5 equiv.) is added dropwise to the reaction mixture. The reaction is stirred at 25° C. until the reaction is complete according to HPLC. The aqueous phase is extracted with ethyl acetate (19.5 vol). The reaction mixture is cooled to 10-15° C. and neutralized with 1M aqueous Na2CO3 solution. The aqueous phase is extracted twice with ethyl acetate (10 vol). The combined organic layers are then washed with water (10 vol). The organic layer is separated into two equal portions (A and B).

[0091] Part A is added to EtOAc (22 vol.) followed by triphenylacetic acid (4.9 g, 1.0 equiv) and stirred at room temperature for 1 h. The reaction is cooled to 0° C. and stirred for 6 h. The solid is isolated by filtration and washed twice with EtOAc (4 vol.). The solid is dried under vacuum to give compound I as an off-white solid (6.1 g, 46.1% yield, 99.2% purity by HPLC).

[0092] Part B is added to a mixture of 22 vol. EtOAc:water 2.8% followed by triphenylacetic acid (4.9 g, 1.0 equiv) and stirred at room temperature for 1 hour. The reaction is cooled to 0° C. and stirred for 6 hours. The solid is isolated by filtration and washed twice with 4 vol. EtOAc:water 2.8%. The solid is dried under vacuum to give compound I as an off-white solid (7.2 g, 54.6% yield, 99.4% purity by HPLC).

[0093] Example 18: Recrystallization of vilanterol triphenylacetate Compound I (6.6 g, 7.2 mmol) is added to a mixture of EtOAc:water 2.8% (50 vol.). The suspension is heated to 45° C. and stirred for 1 h while compound I is dissolved. The solution is cooled to 0° C. and stirred for 6 h. The solid is isolated by filtration and washed twice with EtOAc:water 2.8% (4 vol.). The solid is dried under vacuum to give compound I as an off-white solid (4.4 g, 67.5% yield, 99.6% purity by HPLC).

[0094] Example 19 Recrystallization of vilanterol triphenylacetate Compound I (5.6 g, 7.2 mmol) is added to EtOAc (55 vol.). The suspension is heated to 60° C. and stirred for 1 h while compound I is dissolved. The solution is cooled to 10° C. and stirred for 6 h. The solid is isolated by filtration and washed twice with EtOAc (4 vol.). The solid is dried under vacuum to give compound I as an off-white solid (4.52 g, 81.0% yield, 99.5% purity by HPLC).

Claims

1. A process for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Compound VI) or a pharma- ceutically acceptable salt thereof, comprising the following steps, wherein steps A to B(i) are carried out as a one-pot process: A) coupling compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in an organic solvent; and B) (i) adding a base to the reaction mixture formed in step A to remove the oxazolidinone protecting group to form compound V; (ii) converting compound V into vilanterol (compound VI) or a pharma- ceutically acceptable salt thereof.

2. 13. The method of claim 1 for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Compound VI) or a pharma- ceutically acceptable salt thereof, comprising the steps A to C of: A) coupling compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in an organic solvent; B) adding a base to the reaction mixture formed in step A to remove the oxazolidinone protecting group; and C) adding an acidic solution to the reaction mixture formed in step B to cleave the acetonide protecting group to form vilanterol (compound VI); D) optionally converting compound VI into a pharma- ceutically acceptable salt thereof.

3. 3. The method of claim 1 or 2 for preparing a pharma- ceutically acceptable salt of vilanterol, wherein steps A to D are carried out as a one-pot process comprising the following steps: A) coupling compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (compound III) in the presence of a base in an organic solvent; B) adding a base to the reaction mixture formed in step A to remove the oxazolidinone protecting group; and C) adding an acidic solution to the reaction mixture formed in step B to cleave the acetonide protecting group to form vilanterol (compound VI); D) converting compound VI into a pharma- ceutically acceptable salt thereof.

4. 2. The method of claim 1, wherein there is no isolation of intermediates until compound V is obtained.

5. 3. The process of claim 2, wherein there is no isolation of intermediates until compound VI is obtained.

6. 4. The method of claim 3, wherein there is no isolation of intermediates until the pharma- ceutically acceptable salt of vilanterol (compound VI) is obtained in step D.

7. The method according to any one of claims 1 to 6, wherein the process is carried out in batch mode or continuous flow mode.

8. 8. The process according to any one of claims 1 to 7, wherein the organic solvent in step A is selected from the group consisting of polar aprotic solvents such as dimethylformamide, dimethylsulfoxide, dimethylacetamide, n-methyl-pyrrolidin-2-one, ethers such as tetrahydrofuran, sulfolane or mixtures thereof, preferably DMSO.

9. The process according to any one of claims 1 to 8, wherein the volume of solvent relative to compound II is at least 10 volumes, preferably 25 volumes.

10. The process according to any one of claims 1 to 9, wherein the base used in step A is selected from the group consisting of an alkali metal hydroxide, an alkali metal hydride or an alkali metal alkoxide, preferably potassium tert-butoxide.

11. The process according to any one of claims 1 to 10, wherein in batch mode, the base is used in at least a stoichiometric molar amount or more relative to compound II.

12. The method of claim 11, wherein about 1 to about 1.15 molar equivalents of base relative to compound II are used.

13. The process according to any one of claims 1 to 10, wherein in continuous flow mode, the base is used in at least a stoichiometric molar amount or more relative to compound II.

14. The method of claim 13, wherein about 1.15 to 3 molar equivalents of base relative to compound II are used.

15. The process according to any one of claims 1 to 12, wherein in batch mode, step A is carried out at a temperature of 20 to 30°C, preferably 20 to 25°C.

16. 15. The process according to any one of claims 1 to 10 or 13 to 14, wherein in continuous flow mode, the reaction of compound II with base in step A is carried out at a temperature in the range of 20°C to 100°C, preferably around 20°C, and the flow rate is adjusted to provide a residence time in the range of 0.5 min to 30 min, preferably around 6 min.

17. 17. The process according to any one of claims 1 to 10, or 13 to 14, or 16, wherein in continuous flow mode, the reaction of deprotonated compound II with compound III in step A is carried out at a temperature in the range of 20°C to 100°C, preferably around 60°C, with an adjusted flow rate and a residence time in the range of 0.5 min to 30 min, preferably around 6 min.

18. 16. The process according to any one of claims 1 to 12 or 15, wherein in batch mode, the base used in step B is used in an amount of 1 to 3 molar equivalents relative to compound II, preferably 1.5 molar equivalents relative to compound II.

19. 19. The process according to any one of claims 1 to 12, or 15, or 18, wherein in batch mode, water is used in step B in an amount of 1.5 to 3 molar equivalents relative to compound II, preferably 1.5 molar equivalents relative to compound II.

20. 18. The process of any one of claims 1 to 10, 13 to 14, or 16 to 17, wherein in continuous flow mode, the base used in step B is used in an amount of up to 15 molar equivalents relative to compound II, preferably about 4 to 5 molar equivalents relative to compound II.

21. A process according to any one of claims 1 to 12, or 15, or 18 to 19, wherein in batch mode the reaction is carried out at a temperature of 30 to 65°C, preferably 35 to 50°C.

22. 21. The process of any one of claims 1 to 10, 13 to 14, or 16 to 17, or 20, wherein in continuous flow mode the reaction is carried out at a temperature in the range of 20°C to 150°C, preferably around 80°C.

23. 23. The method of any one of claims 1 to 10, 13 to 14, or 16 to 17, or 20, or 22, wherein in continuous flow mode, in step B, the flow rate is adjusted to provide a residence time in the range of 0.5 min to 30 min, preferably around 4 min.

24. 24. The process according to any one of claims 2 to 23, wherein the acidic solution used in step C is selected from the group consisting of 0.1-1N HCl solution, 1-10% HCl alcoholic solution, HCl dissolved in a suitable organic solvent, e.g. DMF-HCl, ether-HCl, acetic acid-HCl, preferably 1N HCl aqueous solution, or any acidic solution suitable for achieving acetal hydrolysis in step C.

25. 25. The process according to any one of claims 1 to 12, or 15, or 18 to 19, or 21, or 24, wherein in batch mode, step C is carried out at a temperature from about 20°C and 30°C, in particular from about 20°C and 25°C.

26. 25. The method according to any one of claims 1 to 10, 13 to 14, or 16 to 17, or 20, or 22 to 24, wherein in continuous flow mode, step C is carried out at a temperature in the range of 20°C to 100°C, preferably at around 20°C.

27. 27. The method of any one of claims 1 to 10, 13 to 14, or 16 to 17, or 20, or 22 to 24, or 26, wherein in continuous flow mode, in step C, the flow rate is adjusted to provide a residence time in the range of 0.5 min to 30 min, preferably around 10 min.

28. 28. A method for preparing vilanterol triphenylacetate (Compound I) according to any one of claims 1 to 27, comprising reacting Compound VI with triphenylacetic acid to form vilanterol triphenylacetate (Compound I).

29. iii) removing the acetonide protecting group from compound V in an acidic solution to form compound VI; and 4. A method for preparing vilanterol triphenylacetate (compound I) according to any one of claims 1, or 4, or 7-28, comprising the step of: iv) reacting compound VI with triphenylacetic acid to form compound I.

30. A process for preparing vilanterol ((R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; Compound VI) or a pharma- ceutically acceptable salt thereof, comprising coupling the compound (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one (Compound II) with 2-[2-(6-bromohexyloxy)-ethoxymethyl]-1,3-dichlorobenzene (Compound III) and converting the product formed into vilanterol or a pharma- ceutically acceptable salt thereof, wherein no intermediate compound or only one is isolated during the process.